Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

Jorge Cortes, MD, H. Jean Khoury, MD, Sélim Corm, MD, Franck E Nicolini, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, MD, Eric Humphriss, Hagop Kantarjian

Blood (2008) 112 (11): 3239.

https://doi.org/10.1182/blood.V112.11.3239.3239

Published: 2008

Journal Articles

Maintenance Therapy by Glivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation.

Blood (2007) 110 (11): 2812.

https://doi.org/10.1182/blood.V110.11.2812.2812

Published: 2007

Journal Articles

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Franck E. Nicolini, MD, PhD, Emmanuel Bachy, MD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Dominique Bories, MD, PhD, Michel Tulliez, MD, Nathalie Sorel, MD, Francois Guilhot, MD, Laurence Legros, MD, François-Xavier Mahon, MD, PhD, Frédéric Maloisel, MD, Jean-Jacques Kiladjian, MD, PhD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2006) 108 (11): 2190.

https://doi.org/10.1182/blood.V108.11.2190.2190

Published: 2006

Journal Articles

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Franck E. Nicolini, MD, PhD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Nathalie Sorel, PhD, Dominique Bories, MD, PhD, Stéphane Giraudier, MD, PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Jean-Michel Cayuela, MD, François-Xavier Mahon, MD, PhD, Pascale Cony-Makhoul, MD, Jean-Jacques Kiladjian, MD, Olivier Tournilhac, MD, François Guilhot, MD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2005) 106 (11): 3284.

https://doi.org/10.1182/blood.V106.11.3284.3284

Published: 2005

Journal Articles

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Franck E. Nicolini, MD, PhD, Nathalie Grardel, MD, Sandrine Hayette, PhD, Jean-Michel Cayuela, MD, Agnès Buzyn, MD, PhD, Eric Delabesse, MD, Christian Bastard, MD, Odile Blanchet, MD, Nathalie Sorel, PhD, Marie-Josée Mozziconacci, MD, Ali Turhan, MD, PhD, Virginie Eclache, MD, François-Xavier Mahon, MD, PhD, Nicole Dastugue, MD, Eric Legac, MD, Marie-Pierre Gaub, MD, Sélim Corm, MD, Claude Preudhomme, MD, PhD

Blood (2005) 106 (11): 3285.

https://doi.org/10.1182/blood.V106.11.3285.3285

Published: 2005

NARROW

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

Maintenance Therapy by Glivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

Maintenance Therapy by Glivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem Cell Transplantation.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only